CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- DEF 14A Proxy Proxy Statement
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Other events
- PRE 14A Proxy Proxy Statement (Preliminary)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations · Regulation FD disclosure
- 8-K Event Bylaws or fiscal year change
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Regulation FD disclosure · Other events
- 4 Grant or award CFO and Chief Business Officer acquired 33,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 26,700 shares (grant or award)
- 4 Grant or award President and CEO acquired 114,000 shares (grant or award)
- 4 Grant or award Chief Legal Office & Corp Sec acquired 26,800 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 26,700 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
Page 13 of 19 · 365 filings